The Experts below are selected from a list of 687 Experts worldwide ranked by ideXlab platform
H M Vemer - One of the best experts on this subject based on the ideXlab platform.
-
follicular fluid hormone concentrations after ovarian stimulation using Gonadotropin Preparations with different fsh lh ratios ii comparison of hmg and recombinant fsh
International journal of fertility and women's medicine, 1997Co-Authors: I J M Duijkers, W N P Willemsen, H M G Hollanders, C J C M Hamilton, Chris M G Thomas, H M VemerAbstract:OBJECTIVE A small amount of LH is necessary for 17 beta-estradiol production in the ovarian follicle. Human menopausal Gonadotropin (hMG) contains equal amounts of FSH and LH activity, whereas recombinant FSH is a Gonadotropin preparation without LH. The aim of the present randomized study was to investigate whether ovarian stimulation treatment with recombinant FSH or hMG resulted in different steroidal composition of follicular fluid. METHODS Antral fluid from mature follicles was collected in in vitro fertilization cycles and concentrations of testosterone, androstenedione, estrone, estradiol, progesterone, FSH, and LH were determined. Seven patients (27 samples) were treated with hMG, 6 patients (22 samples) with recombinant FSH. RESULTS Androgen, estrogen, progesterone, and FSH concentrations in follicular fluid tended to be lower in the group treated with recombinant FSH, but the variation was large and differences were statistically not significant. CONCLUSION Treatment with a Gonadotropin preparation containing no LH resulted in adequate androgen and estrogen levels in antral fluid of the ovarian follicle in women with normal endocrine profiles, even during pituitary suppression by a GnRH agonist. Apparently, the amount of endogenous LH was sufficient for steroid production within the follicle.
-
follicular fluid hormone concentrations during controlled ovarian hyperstimulation using Gonadotropin Preparations with different fsh lh ratios i comparison of an fsh dominant and a purified fsh preparation
International journal of fertility and women's medicine, 1997Co-Authors: I J M Duijkers, W N P Willemsen, H M G Hollanders, C J C M Hamilton, Chris M G Thomas, H M VemerAbstract:Objective—A small amount of LH is necessary for 17s-estradiol production in the ovarian folli cle. Human menopausal Gonadotropin (hMG) contains equal amounts of PSH and LH activity, whereas recombinant FSH is a Gonadotropin preparation without LH. The aim of the present randomized study was to investigate whether ovarian stimulation treatment with recombinant FSH or hMG resulted in different steroidal composition of follicular fluid. Methods—Antral fluid from mature follicles was collected in in vitro fertilization cycles and concentrations of testosterone, androstenedione, estrone, estradiol, proges terone, FSH, and LH were determined. Seven patients (27 samples) were treated with hMG, 6 patients (22 samples) with recombinant FSH. Results—Androgen, estrogen, progesterone, and FSH concentrations in fol licular fluid tended to be lower in the group treated with recombinant FSH, but the variation was large and differences were statistically not significant. Conclusion—Treatment with a Gonadotropin preparation con taining no LH resulted in adequate androgen and estrogen levels in antral fluid of the ovarian follicle in women with normal endocrine profiles, even during pituitary suppression by a GnRH agonist. Apparently, the am ount of endogenous LH was sufficient for steroid production w ith in the follicle. Int JFertil 42(5):306-310, 1997
I J M Duijkers - One of the best experts on this subject based on the ideXlab platform.
-
follicular fluid hormone concentrations after ovarian stimulation using Gonadotropin Preparations with different fsh lh ratios ii comparison of hmg and recombinant fsh
International journal of fertility and women's medicine, 1997Co-Authors: I J M Duijkers, W N P Willemsen, H M G Hollanders, C J C M Hamilton, Chris M G Thomas, H M VemerAbstract:OBJECTIVE A small amount of LH is necessary for 17 beta-estradiol production in the ovarian follicle. Human menopausal Gonadotropin (hMG) contains equal amounts of FSH and LH activity, whereas recombinant FSH is a Gonadotropin preparation without LH. The aim of the present randomized study was to investigate whether ovarian stimulation treatment with recombinant FSH or hMG resulted in different steroidal composition of follicular fluid. METHODS Antral fluid from mature follicles was collected in in vitro fertilization cycles and concentrations of testosterone, androstenedione, estrone, estradiol, progesterone, FSH, and LH were determined. Seven patients (27 samples) were treated with hMG, 6 patients (22 samples) with recombinant FSH. RESULTS Androgen, estrogen, progesterone, and FSH concentrations in follicular fluid tended to be lower in the group treated with recombinant FSH, but the variation was large and differences were statistically not significant. CONCLUSION Treatment with a Gonadotropin preparation containing no LH resulted in adequate androgen and estrogen levels in antral fluid of the ovarian follicle in women with normal endocrine profiles, even during pituitary suppression by a GnRH agonist. Apparently, the amount of endogenous LH was sufficient for steroid production within the follicle.
-
follicular fluid hormone concentrations during controlled ovarian hyperstimulation using Gonadotropin Preparations with different fsh lh ratios i comparison of an fsh dominant and a purified fsh preparation
International journal of fertility and women's medicine, 1997Co-Authors: I J M Duijkers, W N P Willemsen, H M G Hollanders, C J C M Hamilton, Chris M G Thomas, H M VemerAbstract:Objective—A small amount of LH is necessary for 17s-estradiol production in the ovarian folli cle. Human menopausal Gonadotropin (hMG) contains equal amounts of PSH and LH activity, whereas recombinant FSH is a Gonadotropin preparation without LH. The aim of the present randomized study was to investigate whether ovarian stimulation treatment with recombinant FSH or hMG resulted in different steroidal composition of follicular fluid. Methods—Antral fluid from mature follicles was collected in in vitro fertilization cycles and concentrations of testosterone, androstenedione, estrone, estradiol, proges terone, FSH, and LH were determined. Seven patients (27 samples) were treated with hMG, 6 patients (22 samples) with recombinant FSH. Results—Androgen, estrogen, progesterone, and FSH concentrations in fol licular fluid tended to be lower in the group treated with recombinant FSH, but the variation was large and differences were statistically not significant. Conclusion—Treatment with a Gonadotropin preparation con taining no LH resulted in adequate androgen and estrogen levels in antral fluid of the ovarian follicle in women with normal endocrine profiles, even during pituitary suppression by a GnRH agonist. Apparently, the am ount of endogenous LH was sufficient for steroid production w ith in the follicle. Int JFertil 42(5):306-310, 1997
Hans M Vemer - One of the best experts on this subject based on the ideXlab platform.
-
human chorionic Gonadotropin in commercial human menopausal Gonadotropin Preparations
Fertility and Sterility, 1993Co-Authors: Peter G W Stokman, Renato De Leeuw, Han A G W Van Den Wijngaard, H J Kloosterboer, Hans M VemerAbstract:Several studies indicated the presence of an hCG-immunoreactive substance in commercial hMG Preparations. Because hCG represents LH activity with a relatively very long half-life, differences between hMG Preparations with respect to hCG content could imply clinical differences. To investigate whether there is any difference in this respect between the two most widely used hMG Preparations, we measured the hCG content of ampules of Humegon and Pergonal retrieved from the market, together representing 51 separate production batches, with one or more different specific immunological assays. There are no significant differences between Humegon and Pergonal with respect to the mean hCG level per ampule as measured by RIA, ELISA, and Delfia. The batch-to-batch consistency for Humegon is higher.
Anders Nyboe Andersen - One of the best experts on this subject based on the ideXlab platform.
-
antimullerian hormone in Gonadotropin releasing hormone antagonist cycles prediction of ovarian response and cumulative treatment outcome in good prognosis patients
Fertility and Sterility, 2013Co-Authors: Joancarles Arce, Anders Nyboe Andersen, Antonio La Marca, Bjarke Mirner Klein, Richard FlemingAbstract:Objective To assess the relationships between serum antimullerian hormone (AMH) and ovarian response and treatment outcomes in good-prognosis patients undergoing controlled ovarian stimulation using a Gonadotropin-releasing hormone (GnRH) antagonist protocol. Design Secondary analysis of data prospectively collected in a randomized, assessor-blind trial comparing two different Gonadotropin Preparations with respect to ongoing pregnancy rate. Setting Twenty-five centers in seven countries. Patient(s) 749 women, aged 21 to 34 years, with primary diagnosis of infertility being unexplained infertility or mild male factor infertility and with serum follicle-stimulating hormone (FSH) level 1–12 IU/L and antral follicle count (AFC) ≥10. Intervention(s) Controlled ovarian stimulation with highly purified human menopausal Gonadotropin (hphMG) or recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer and potential subsequent 1-year cryopreserved blastocyst replacement in natural cycles. Main Outcome Measure(s) Relationships between AMH at start of stimulation and ovarian response and treatment outcome. Result(s) Serum AMH concentration was strongly correlated with oocyte yield: AMH accounted for 85%, FSH for 14%, and inhibin B and AFC for Conclusion(s) There is a positive relationship between AMH and oocyte yield in GnRH antagonist cycles, and AMH is the best predictor for identifying patients with poor and high ovarian response. The positive association between AMH and cumulative live-birth rates after fresh and cryopreserved cycles reflects the availability of more oocytes/blastocysts, not higher quality. Clinical Trial Registration Number NCT00884221.
-
a randomized assessor blind trial comparing highly purified hmg and recombinant fsh in a gnrh antagonist cycle with compulsory single blastocyst transfer
Fertility and Sterility, 2012Co-Authors: Paul Devroey, Antonio Pellicer, Anders Nyboe AndersenAbstract:Objective To compare the efficacy and safety of highly purified menotropin (hphMG) and recombinant FSH (rFSH) for controlled ovarian stimulation in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Design Randomized, open-label, assessor-blind, parallel groups, multicenter, noninferiority trial. Setting Twenty-five infertility centers in seven countries. Patient(s) Seven hundred forty-nine women. Intervention(s) Controlled ovarian stimulation with hphMG or rFSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer on day 5 in one fresh or subsequent frozen blastocyst replacement in natural cycles initiated within 1 year of each patient's start of treatment. Main Outcome Measure(s) Ongoing pregnancy (primary end point) and live birth rates, as well as pharmacodynamic parameters. Result(s) The ongoing pregnancy rate after a fresh cycle was 30% with hphMG versus 27% with rFSH for the per-protocol (PP) population and 29% versus 27% for the intention-to-treat (ITT) population. Noninferiority of hphMG compared to rFSH was established. Considering frozen cycles initiated within 1 year, the cumulative live birth rate for a single stimulation cycle was 40% and 38% for women treated with hphMG and rFSH, respectively (both PP and ITT). Significant differences in pharmacodynamic end points were found between the two Gonadotropin Preparations. Conclusion(s) Highly purified hMG is at least as effective as rFSH in GnRH antagonist cycles with compulsory single-blastocyst transfer. Clinical Trial Registration Number NCT00884221.
Theologos M Michaelidis - One of the best experts on this subject based on the ideXlab platform.
-
interplay between mtor and hippo signaling in the ovary clinical choice guidance between different Gonadotropin Preparations for better ivf
Frontiers in Endocrinology, 2021Co-Authors: Kyriaki Papageorgiou, Eirini Mastora, Athanasios Zikopoulos, Maria Grigoriou, Ioannis Georgiou, Theologos M MichaelidisAbstract:One of the most widely used types of assisted reproduction technology is the in vitro fertilization (IVF), in which women undergo controlled ovarian stimulation through the administration of the appropriate hormones to produce as many mature follicles, as possible. The most common hormone combination is the co-administration of Gonadotropin-releasing hormone (GnRH) analogues with recombinant or urinary-derived follicle-stimulating hormone (FSH). In the last few years, scientists have begun to explore the effect that different Gonadotropin Preparations have on granulosa cells' maturation and apoptosis, aiming to identify new predictive markers of oocyte quality and successful fertilization. Two major pathways that control the ovarian development, as well as the oocyte-granulosa cell communication and the follicular growth, are the PI3K/Akt/mTOR and the Hippo signaling. The purpose of this article is to briefly review the current knowledge about the effects that the different Gonadotropins, used for ovulation induction, may exert in the biology of granulosa cells, focusing on the importance of these two pathways, which are crucial for follicular maturation. We believe that a better understanding of the influence that the various ovarian stimulation protocols have on these critical molecular cascades will be invaluable in choosing the best approach for a given patient, thereby avoiding cancelled cycles, reducing frustration and potential treatment-related complications, and increasing the pregnancy rate. Moreover, individualizing the treatment plan will help clinicians to better coordinate assisted reproductive technology (ART) programs, discuss the specific options with the couples undergoing IVF, and alleviate stress, thus making the IVF experience easier.